KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Idexx Laboratories (IDXX) Income from Continuing Operations (2016 - 2026)

Idexx Laboratories has reported Income from Continuing Operations over the past 17 years, most recently at 248188000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 14.82% year-over-year to 248188000.0; the TTM value through Dec 2025 reached 1059464000.0, up 19.33%, while the annual FY2025 figure was 1059464000.0, 19.33% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 248188000.0 at Idexx Laboratories, down from 274610000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 293989000.0 in Q2 2025 and troughed at 131979000.0 in Q2 2022.
  • A 5-year average of 210815300.0 and a median of 208260000.0 in 2021 define the central range for Income from Continuing Operations.
  • Biggest five-year swings in Income from Continuing Operations: skyrocketed 82.64% in 2021 and later tumbled 34.86% in 2022.
  • Year by year, Income from Continuing Operations stood at 162771000.0 in 2021, then grew by 5.8% to 172207000.0 in 2022, then increased by 12.96% to 194521000.0 in 2023, then grew by 11.12% to 216149000.0 in 2024, then increased by 14.82% to 248188000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for IDXX at 248188000.0 in Q4 2025, 274610000.0 in Q3 2025, and 293989000.0 in Q2 2025.